Genetic aspects of malignant epithelial ovarian tumours;Genetické aspekty maligních epiteliálních nádorů ovaria

Ceska Gynekologie

Volumn 70, Issue 4, 2005, Pages 299-306

  Jančárková, Natalie ^a   Krkavcova M ^a   Janashia, M ^a   Freitag, P ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Genetic alteration; Mismatch repair genes; Oncogenes; Ovarian cancer; Tumor supressor genes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DNA REPAIR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOME IMPRINTING; HUMAN; MISMATCH REPAIR; ONCOGENE; ONCOGENE RAS; OVARY CANCER; OVARY TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA; DNA REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENES;

EID: 23244455325     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Afify, A. M., Werness, B. A., Mark, H. F. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp. Mol. Pathol., 1999, 66, 2, p. 163-169.
2. Arnold, J. M., Woollatt, E., Chenevix-Trench, G. Chromosome 8 genetic analysis and phenotypic characterization of 21 ovarian cancer cell lines. Cancer Genet. Cytogenet., 2002, 139, 2, p. 109-114.
3. Atkin, N. B. Aneuploidy in carcinomas may be initiated by the acquisition of a single trisomy. Cytogenet. Genome Res. 2003, 101, 2, p. 99-102.
4. Aunoble, B., Sanches, R., Didier, E., Bignon, Y. J. Major oncogenes and tumor supressor genes involved in epithelial ovarian cancer (rev.). Int. J. Oncol., 2000, 16, 3, p. 567-576.
5. Baekelandt, M., Kristensen, G. B., Nesland, J. M., et al. Clinical Significance of Apoptosis-Related Factors p53, Mdm2 and Bcl-2 in Advanced Ovarian Cancer. J. Clin. Oncol., 1999, 17, 7, p. 2061.
6. Bartoňková, H., Foretová, L., Helmichová, E., Kalábová, R., et al. Doporučené zásady péče o nemocné s nádory prsu a vaječní ku a zdravé osoby se zárodečnými mutacemi genů BRCA1 a BRCA2. Klin. Onkol., 2003, 16, 1, s. 28-34.
7. Bayani, J., Brenton, J. D., Macgregor, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, Comparative genomic hybridization and expression microarrays. Cancer Res., 2002, 62, 12, p. 3466-3476.
8. Berchuk, A. Biomarkers in the ovary. J. Cell Biochem., 1995, Suppl. 23, p. 223-226.
9. Bernardini, M., Weberpals, J., Squire, J. A. The use of cytogenetics in understanding ovarian cancer. Biomed. Pharmacother. 2004, 58, 1, p. 17-23.
10. Bogle, P., Maisonneuuve, P., Autlier, P. Update on cancer control in women. Int. J. Gyn. Obst., 2000, 70, p. 263-303.
11. Bosze, P., et al. Concensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur. J. Gynaec. Oncol., 2000, 21, 5, p. 513-526.
12. Byrom, J., Mudaliar, V., Redman, C. W., et al. Loss of heterozygosity at chromosome 9q22-31 is a frequent and earl event in ovarian tumors. Int. J. Oncol., 2004, 24, 5, p. 1271-1277.
13. Cvetkovic, D. Early events in ovarian oncogenesis. Reprod. Biol. Endocrinol, 2003, 68, 1.
14. Deger, R. B., Shamim, A. F., Noumoff, J. S. Karyotypic analysis of 32 malignant epithelial ovarian tumors. Cancer Genet. Cytogenet., 1997, 96, p. 166-173.
15. Duesberg, P. H. Are cancers dependent on oncogenes or on aneuploidy? Cancer Genet. Cytogenet., 2003, 143, 1, p. 89-91.
16. Engel, H., Friedrich, J., Kleespies, C., et al. Detection of chromosomal aberrations in tumor cells and tumor infiltrating lymphocytes by molecular cytogenetics in patients with gynecological cancer. Cancer Genet. Cytogenet., 1998, 106, 2, p. 159-165.
17. Evans, M. F., McDicken, I. W., Herrington, C. S. Numerical abnormalities of chromosomes 1, 11, 17 and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours. J. Pathol., 1999, 189, 1, p. 53-99.
18. Faruqi, S. A., Nuomoff, M. J., Deger, R. B., et al. Trisomy 21 as the only recurrent chromosomal anomaly in a clinically aggressive ovarian carcinoma. Cancer Genet. Cytogenet., 2002, 138, p. 165-168.
19. Gospodarowicz, M. K. et al. Prognostic factors in cancer. 2nd ed., New York: UICC. Wiley-Liss, 2001, 809 p.
20. Greggi, S., Macuso, S., Pecorelli, S. Familial and hereditary cancer in women. Milano: Poletto Editore, 1999, 180 p.
21. Green, J. A., Anastasopoulou, A., Duffaud, F., et al. Predictive factors for response in advanced ovarian cancer: For the translation Research Group of the EORTC-Gynecological Cancer Cooperative Group. Ann. Oncol., 2000, 11, 4, p. 85.
22. Guan, X. Y., Sham, J. S., Tang, T. C., et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res., 2001, 61, 0, p. 3806-3809.
23. Hauptmann, S., Denkert, C., Koch, I., et al. Genetic alterations in epithelial ovarian tumors analyzed by comprative genomic hybridization. Hum. Pathol., 2002, 33, 6, p. 632-641.
24. Hoglund, M., Gisselsson, D., Hansen, G. B., et al. Ovarian carcinoma develops through multiple modes of chromosom evolution. Cancer Res., 2003, 63, 12, p. 3378-3385.
25. Hoskins, W. J., Perez, C. A., Young, R. C. Principles and Practice of Gynecologic Oncology. Third Edition, Philadelphia: Lippincott Williams and Wilkins, 2000, 1268 p.
26. Hu, J., Khanna, V., Jones, M. W., Surti, U. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis. Gynecol. Oncol., 2003, 89, 3, p. 369-375.
27. Huang, N. F., Gupta, M., Varghese, S., et al. Detection of numerical chromosomal abnormalities in epithelial ovarian neoplasms by fluorescence in situ hybridization (FISH) and a review of the current literature. Appl. Immunohistochem. Mol. Morphol., 2002, 10, 2, p. 187-193.
28. Israeli, O., Gotlieb, W. H., Friedman, E., et al. Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. Gynecol. Oncol., 2003, 90, 3, p. 629-636.
29. Israeli, O., Gotlieb, W. H., Friedman, E. et al. Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet. Cytogenet., 2004, 154, 1, p. 16-24.
30. Jančárková, N., Zikán, M., Pohlreich, P., et al. Detekce a výskyt mutací genu BRCA1 u pacientek s karcinomem prsu a ovaria. Čes. Gynek., 2003, 68, 1, p. 11-16.
31. Jazaeri, A. A., Lu, K., Schmandt, R., Harris, C. P., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog., 2003, 36, 2, p. 53-59.
32. Jin, Y., Zhang, H., Tsao, S. W., et al. Cytogenetic and molecular genetic characterization of immortalized human ovarian surface epithelial cell lines: consistent loss of chromosome 13 and amplification of chromosome 20. Gynecol Oncol., 2004, 92, s. 183-191.
33. Kiechle-Schwarz, M., Bauknecht, T., Schmidt, J., et al. Recurrent cytogenetic aberrations in human ovarian carcinomas. Cancer Detect. Prev., 1995, 19, 3, p. 234-243.
34. Kim, G. J., Kim, J. O., Hong, E. K., et al. Detection of genetic alteration in Korean ovarian carcinomas by degenerate oligonucleotide primed polymerase chain reaction - comparative genomic hybridization. Cancer Genet. Cytogenet., 2003, 147, 1, p. 23-27.
35. Kurzrock, R., Talpaz, M. Molecular biology in cancer medicine. Sec.Edition, London: Martin Dunitz Ltd., 1999, 679 p.
36. Laframboise, S., Chapman, W., McLaughlin, J., Andrulis, I. L. p53 Mutations in epithelial ovarian cancers. Possible role in predicting chemoresistance. Cancer J., 2000, 6. 5, p. 302-308.
37. Lamerz, R. Role of tumour markers, cytogenetics. Ann Oncol., 1999, 10, 4, p. 145-149.
38. Langston, A. A., Ostrander, E. A. Hereditary ovarian cancer. Curr. Opin. Obstet. Gynec., 1999, 9, p. 3-7.
39. Lassus, H., Laitinen, M. P., Anttonen, M., et al. Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4. Lab. Invest., 2001, 81, 4, p. 517-526.
40. Launonen, V., Mannermaa, A., Stenback, F., et al. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16 and 17 in ovarian cancer. Cancer Genet. Cytogenet., 2000, 122, 1, p. 49-54.
41. Liu, Y., Ganesan, T. S. Tumour supressor genes in sporadic epithelial ovarian cancer. Reproduction, 2002, 123, 3, p. 341-353.
42. Lynch, H. T., Casey, M. J., Lynch, J., et al. Genetics and ovarian carcinoma. Sem. Oncol., 1998, 25, 3, p. 265-280.
43. Mazurek, A., Niklinski, J., Laudanski, T., Pluygers, E. Clinical tumorus markers in ovarian cancer. Eur. J. Cancer Prev., 1998, 7, 1, p. 23-35.
44. Modugno, F. and Ovarian Cancer and High Risk Women Symposium Presenters. Ovarian cancer and high-risk women - implications for prevention, screening and early detection. Gynecol. Oncol., 2003, 91, 1, p. 15-31.
45. Otová, B., Soukup, F. Biologie člověka pro bakalářské studkum na lékařských fakultách. Praha: Karolinum 1998, 102 s.
46. Partheen, K., Levan, K., Osterberg, L., et al. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogenous group regarding survival, surgical outcome and substage. Genes Chromosomes Cancer, 2004, 40, 4, p. 342-348.
47. Patel, A. S., Hawkins, A. L., Griffin, C. A. Cytogenetics and cancer.: Curr. Opin. Oncol., 2000, 12, 1, p. 62-67.
48. Pejovic, T., Heim, S., Mandahl, N., et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer, 1992, 4, 1, p. 58-68.
49. Pospíšilová, S., Vojtěšek, B. Protein p21WAF1 a jeho úloha v regulaci buněčného cyklu. Klin. Onkol., 2000, 13, 1, p. 13-16.
50. Rao, P. H., Harris, C. P., Lu, X. Y., et al. Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer, 2002, 33, p. 123-132.
51. Rejthar, A., Vojtěšek, B. Obecná patologie nádorového růstu. Praha: Grada Publishing, 2002, 206 s.
52. Schildkraut, J. M., Halabi, S., Bastos, E., et al. Prognostic factors in early-onset epithelial ovarian cancer: population-based study. Obstet. Gynecol., 2000, 95, 1, p. 119-127.
53. Schwartz, D. R., Kardia, S. L., Shedden, K. A., et al. Gene expression in ovarian cancer reflects both morphology and biological behaviour, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res.. 2002, 62, 16, p. 4722-4729.
54. Seki, A., Yoshinouchi, M., Seki, N., et al. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int. J. Oncol., 2000, 17, p. 103-106.
55. Sham, J. S. T., Tang, T. C.-M., Fang, Y., et al. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet. Cytogenet., 2002. 133, 1, p. 39-44.
56. Shelling, A. N., Cooke, L. E., Ganesan, T. S. The genetic analysis of ovarian cancer. Br. J. Cancer, 1995, 72, 3. p. 521-527.
57. Sonoda, G., Palazzo, J., du Manoir, S., et al. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24 and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer, 1997, 20, 4, p. 320-328.
58. Stewart, B. W., Kleihues, P. (Eds.): World Cancer Report. Lyon: IARCPress, 2003, 351 s.
59. Struski, S., Doco-Fenzy, M., Koehler, M., et al. Cytogenetic evolution of human ovarian cell lines associated with chemoresistance and loss of tumorigenicity. Anal. Cell Pathol., 2003, 25, 3, p. 115-122.
60. Suzuki, S., Moore II, D. H., Ginzinger, D. G., et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res., 2000, 60, 19, p. 5382-5385.
61. Šimičková, M., Černoch, M.: Význam stanovení aktivity telomerázy v onkologii. Klin. Onkol., 1999, 12, 3, p. 73-77.
62. Šmardová, J. Vůdčí gen P53: zpráva z konference. Klin.Onkol., 2003, 16, 5, p. 238-239.
63. Taetle, R., Aickin, M., Yang, J. M., et al. Chromosome abnormalities in ovarian adenocarcinoma. I Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer, 1999, 25, 3, p. 290-300.
64. Tavassoli, M., Steingrimsdottir, H., Pierce, E. et al. Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and indentifies a tumour supressor gene locus at 5q 13.1-21. Cancer, Br J. 1996, 74, 1, p. 115-119.
65. Teixeira, M. R. Combined classical and molecular cytogenetic analysis of cancer. Eur. J. Cancer, 2002, 38, 12, p. 1580-1584.
66. Thompson, F. H., Taetel, R., Trent, J., et al. Band 1p36 Abnormalities and t(l;17) in Ovarian Carcinoma. Cancer Genet. Cytogenet. 1997, 96, p. 106-110.
67. Tonnies, H. Modern molecular cytogenetic techniques in genetic diagnostics. Trends Mol. Med., 2002, 8, 6, p. 246-250.
68. Umayahara, K., Numa, F., Inokuma, A., et al. Genetic alterations related to lymph node metastasis and peritoneal dissemination in epithelial ovarian cancers. Oncol. Rep., 2002, 9, 5, p. 1115-1119.
69. Wan, M., Suns, T., Vyas, R., et al. Supression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene, 1999, 18, 8, p. 1545-1551.
70. Wang, N. Cytogenetics and Molecular Genetics of Ovarian Cancer. Am. J. Med. Genet., 2002, 115, p. 157-163.
71. Wolf, N. G., Abdul-karim, F. W., Schork, N. J., Scwartz, S. Origins of heterogenous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential and fully malignant components. Am. J. Pathol., 1996, 149, 2, p. 511-520.
72. Zheng, J. P., Robinson, W. R., Ehlen, T., et al. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6 and 11 and HER-2/neu gene amplification. Cancer Res., 1991, 51, 15, p. 4045-4051.
73. Žaloudík, J., Vyzula, R., Dušek, L. Potřebujeme prediktivní onkologii. Klin.Onkol., 1999, 12, 3, p. 110-111.